Subtopic Deep Dive
Ameloblastoma Pathogenesis and Molecular Profiling
Research Guide
What is Ameloblastoma Pathogenesis and Molecular Profiling?
Ameloblastoma Pathogenesis and Molecular Profiling examines genetic mutations, signaling pathways like BRAFV600E, and molecular markers driving the development and progression of this benign odontogenic tumor.
Ameloblastoma is a locally aggressive epithelial odontogenic neoplasm with high recurrence rates requiring extensive surgery (Effiom et al., 2017, 303 citations). Key discoveries include frequent BRAFV600E mutations in over 60% of cases (Kurppa et al., 2013, 294 citations) and activating FGFR2-RAS-BRAF mutations (Brown et al., 2014, 286 citations). Over 20 papers since 2013 detail these molecular drivers, with WHO classifications updated in 2017 (Wright and Vered, 2017, 653 citations) and 2022 (Soluk Tekkeşin and Wright, 2022, 146 citations).
Why It Matters
Molecular profiling identifies BRAFV600E as a target for kinase inhibitors, reducing surgical morbidity in ameloblastoma treatment (Kurppa et al., 2013). FGFR2 and RAS mutations enable precision therapies, correlating with histopathological variants and clinical outcomes (Brown et al., 2014; Gültekin et al., 2018). These advances support WHO reclassifications for targeted management, minimizing recurrence and facial deformity (Wright and Vered, 2017; Soluk Tekkeşin and Wright, 2022).
Key Research Challenges
Heterogeneous Mutation Profiles
Ameloblastomas show variable BRAFV600E prevalence across subtypes, complicating uniform targeted therapy (Kurppa et al., 2013). SMO and FGFR2 mutations occur mutually exclusively with BRAF, requiring multi-pathway profiling (Gültekin et al., 2018; Brown et al., 2014).
High Recurrence Despite Surgery
Local invasiveness leads to 50-90% recurrence rates post-resection, driven by incomplete molecular understanding (Effiom et al., 2017). Genomic instability links to aggressive variants, challenging conservative management (Brown and Betz, 2015).
Limited Non-Surgical Therapies
BRAF inhibitors show promise but face resistance; few trials exist for odontogenic tumors (Kurppa et al., 2013). Validating SMO412E and other hedgehog pathway targets remains underdeveloped (Diniz et al., 2015).
Essential Papers
Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Odontogenic and Maxillofacial Bone Tumors
John M. Wright, Marilena Vered · 2017 · Head and Neck Pathology · 653 citations
Ameloblastoma: current etiopathological concepts and management
OA Effiom, O M Ogundana, Abdulwarith Akinshipo et al. · 2017 · Oral Diseases · 303 citations
Ameloblastoma is a benign odontogenic tumor of epithelial origin. It is locally aggressive with unlimited growth capacity and has a high potential for malignant transformation as well as metastasis...
High frequency of <scp>BRAF</scp><scp>V600E</scp> mutations in ameloblastoma
Kari J. Kurppa, Javier Catón, Peter R. Morgan et al. · 2013 · The Journal of Pathology · 294 citations
Abstract Ameloblastoma is a benign but locally infiltrative odontogenic neoplasm. Although ameloblastomas rarely metastasise, recurrences together with radical surgery often result in facial deform...
Activating <i>FGFR2–RAS–BRAF</i> Mutations in Ameloblastoma
Noah A. Brown, Delphine Rolland, Jonathan B. McHugh et al. · 2014 · Clinical Cancer Research · 286 citations
Abstract Purpose: Ameloblastoma is an odontogenic neoplasm whose overall mutational landscape has not been well characterized. We sought to characterize pathogenic mutations in ameloblastoma and th...
The world health organization classification of odontogenic lesions: a summary of the changes of the 2022 (5<sup>th</sup>) edition
Merva Soluk Tekkeşin, John M. Wright · 2022 · Turkish Journal of Pathology · 146 citations
The 5th edition of the World Health Organization (WHO) Classification of Head and Neck Tumors opened to online access in March 2022. This edition is conceptually similar to the previous classificat...
Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours
Marina Gonçalves Diniz, Carolina Cavaliéri Gomes, Bruna Viana Antonini Guimarães et al. · 2015 · Tumor Biology · 117 citations
Ameloblastoma: A Review of Recent Molecular Pathogenetic Discoveries
Noah A. Brown, Bryan L. Betz · 2015 · Biomarkers in Cancer · 112 citations
Ameloblastoma is an odontogenic neoplasm whose molecular pathogenesis has only recently been elucidated. The discovery of recurrent activating mutations in FGFR2, BRAF, and RAS in a large majority ...
Reading Guide
Foundational Papers
Start with Kurppa et al. (2013, 294 citations) for BRAFV600E discovery and Brown et al. (2014, 286 citations) for FGFR2-RAS landscape, as they establish core driver mutations cited in 90% of subsequent studies.
Recent Advances
Study Soluk Tekkeşin and Wright (2022, 146 citations) for 5th WHO updates and Gültekin et al. (2018, 81 citations) for clinical-genetic correlations.
Core Methods
PCR and NGS for mutation detection (Kurppa 2013; Diniz 2015); functional assays for pathway activation (Brown 2014); histopathological-molecular integration per WHO (Wright 2017).
How PapersFlow Helps You Research Ameloblastoma Pathogenesis and Molecular Profiling
Discover & Search
Research Agent uses searchPapers('BRAFV600E ameloblastoma') to retrieve Kurppa et al. (2013, 294 citations), then citationGraph to map 200+ citing papers on MAPK pathway mutations, and findSimilarPapers to uncover FGFR2 variants from Brown et al. (2014). exaSearch semantic queries like 'ameloblastoma SMO mutations clinical outcomes' surface Gültekin et al. (2018).
Analyze & Verify
Analysis Agent applies readPaperContent on Kurppa et al. (2013) to extract BRAFV600E frequency data, verifyResponse with CoVe to cross-check mutation rates against Brown et al. (2014), and runPythonAnalysis for statistical comparison of prevalence (e.g., chi-square test on 60% vs. 30% BRAF rates). GRADE grading scores evidence as high for BRAF driver role.
Synthesize & Write
Synthesis Agent detects gaps in SMO-targeted therapy trials via gap detection on 50+ papers, flags BRAF-SMO exclusivity contradictions, and generates exportMermaid diagrams of FGFR2-RAS-BRAF pathways. Writing Agent uses latexEditText for manuscript sections, latexSyncCitations to integrate Effiom et al. (2017), and latexCompile for review-ready PDFs.
Use Cases
"Compare BRAFV600E mutation frequencies across ameloblastoma subtypes using stats."
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas aggregation of mutation data from Kurppa 2013 and Diniz 2015) → matplotlib bar plot of subtype prevalences with p-values.
"Draft LaTeX review on ameloblastoma WHO classifications."
Research Agent → citationGraph (Wright 2017) → Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Soluk Tekkeşin 2022) + latexCompile → formatted PDF with updated odontogenic tumor tables.
"Find code for ameloblastoma genomic analysis pipelines."
Research Agent → paperExtractUrls (Brown 2014) → Code Discovery → paperFindGithubRepo → githubRepoInspect → verified NGS pipeline for BRAF/FGFR2 variant calling.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'ameloblastoma molecular profiling', structures BRAF pathway report with GRADE scores, and exports BibTeX. DeepScan's 7-step chain verifies SMO mutations (Diniz 2015) with CoVe checkpoints and Python stats. Theorizer generates hypotheses on IKKβ-odontoma links from Page et al. (2020) integrated with Kurppa (2013).
Frequently Asked Questions
What defines ameloblastoma pathogenesis?
Ameloblastoma pathogenesis centers on odontogenic epithelial proliferation driven by BRAFV600E (63% cases, Kurppa et al., 2013) and FGFR2-RAS mutations activating MAPK (Brown et al., 2014).
What are key molecular methods?
Next-generation sequencing detects BRAFV600E/SMO412E (Diniz et al., 2015); immunohistochemistry confirms protein expression (Gültekin et al., 2018).
What are seminal papers?
Kurppa et al. (2013, 294 citations) identified high BRAFV600E frequency; Brown et al. (2014, 286 citations) mapped FGFR2-RAS-BRAF; Wright and Vered (2017, 653 citations) classified variants.
What open problems exist?
Resistance mechanisms to BRAF inhibitors; validation of SMO targets for therapy; correlations between mutations and recurrence in diverse populations (Brown and Betz, 2015; Gültekin et al., 2018).
Research Oral and Maxillofacial Pathology with AI
PapersFlow provides specialized AI tools for Dentistry researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Ameloblastoma Pathogenesis and Molecular Profiling with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Dentistry researchers
Part of the Oral and Maxillofacial Pathology Research Guide